Goldencross Pharma Limited - Charges

Every charge - open or closed - that lenders have registered against Goldencross Pharma Limited, with the most recent activity at the top.

2000-01-21 Mumbai, Maharashtra Active Unlisted Active Compliant
Share
View plans
GP Goldencross Pharma Limited
Open charges
0
0.00
Closed charges
3
91.50 cr
Total
3
91.50 cr
Open vs closed
Top charge holders (by amount)
Top lenders
#LenderChargesAmount
1 The Hongkong And Shanghai Banking Corpor… 1 90.00 cr
2 Credit Lyonnias 2 1.50 cr
All charges (3) - latest first
Charge ID Charge holder Created Modified Satisfied Amount Status
10142776 The Hongkong And Shanghai Banking Corporation Limited 03 Feb 2009 31 Mar 2009 18 Jul 2012 90.00 cr Closed
90237480 Credit Lyonnias 18 Mar 2002 - 26 Mar 2019 75.00 Lakh Closed
90237477 Credit Lyonnias 08 Mar 2002 - 26 Mar 2019 75.00 Lakh Closed
Frequently Asked Questions - Charges & borrowings
What do "charges" mean for Goldencross Pharma Limited?
Charges are registrable security interests-typically loans or credit facilities-filed with MCA against Goldencross Pharma Limited (CIN: U24239MH2000PLC123766). They indicate assets or undertakings pledged to lenders or charge holders.
What is the difference between open and closed charges?
Open charges are active or not yet fully discharged; closed (or satisfied) charges are recorded as settled or released. Counts and amounts on this page follow the statuses shown in the charge list.
How should I read the open vs closed amounts?
Open and closed amounts summarise registrable amounts by status for quick comparison; individual rows may show charge-specific amounts, holders, and dates for verification.
Who are the "top lenders" or charge holders?
Top lenders group charge holders by bank or institution name and approximate exposure so you can see which lenders appear most prominently for Goldencross Pharma Limited.
Where can I cross-check financial or ownership context?
Pair this Charges view with the Financial and Ownership sections on this company's V1 profile for loans in financial statements and cap table context alongside MCA charge filings.